Immune Therapies in Non-Muscle Invasive Bladder Cancer

Philip L. Ho, Stephen Williams, Ashish M. Kamat

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Non-muscle invasive bladder cancer (NMIBC) continues to be a challenging disease to manage. Treatment involves transurethral resection and, often, intravesical therapy. Appropriate patient selection, accurate staging, and morphological characterization are vital in risk-stratifying patients to those who would most benefit from receiving intravesical therapy. Bacillus of Calmette and Guérin (BCG) continues to be the first-line agent of choice for patients with intermediate- and high-risk NMIBC. Treatment should begin with the standard induction course of 6 weekly treatments. The inclusion of subsequent maintenance courses of BCG is imperative to optimal therapeutic response. While patients with intermediate-risk disease should receive 1 year of maintenance therapy, high-risk patients benefit from up to 3 years of maintenance therapy. BCG use should not be used in low-risk patients with de novo Ta, low-grade, solitary,

Original languageEnglish (US)
JournalCurrent Treatment Options in Oncology
Volume16
Issue number2
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Bacillus
Therapeutics
Proxy
Patient Selection
Maintenance

Keywords

  • BCG
  • Bladder Cancer
  • Immune Therapy
  • Immunology
  • Non Invasive
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Immune Therapies in Non-Muscle Invasive Bladder Cancer. / Ho, Philip L.; Williams, Stephen; Kamat, Ashish M.

In: Current Treatment Options in Oncology, Vol. 16, No. 2, 2015.

Research output: Contribution to journalArticle

@article{e17f33cc87d040398c4de0772e965b5e,
title = "Immune Therapies in Non-Muscle Invasive Bladder Cancer",
abstract = "Non-muscle invasive bladder cancer (NMIBC) continues to be a challenging disease to manage. Treatment involves transurethral resection and, often, intravesical therapy. Appropriate patient selection, accurate staging, and morphological characterization are vital in risk-stratifying patients to those who would most benefit from receiving intravesical therapy. Bacillus of Calmette and Gu{\'e}rin (BCG) continues to be the first-line agent of choice for patients with intermediate- and high-risk NMIBC. Treatment should begin with the standard induction course of 6 weekly treatments. The inclusion of subsequent maintenance courses of BCG is imperative to optimal therapeutic response. While patients with intermediate-risk disease should receive 1 year of maintenance therapy, high-risk patients benefit from up to 3 years of maintenance therapy. BCG use should not be used in low-risk patients with de novo Ta, low-grade, solitary,",
keywords = "BCG, Bladder Cancer, Immune Therapy, Immunology, Non Invasive, Treatment",
author = "Ho, {Philip L.} and Stephen Williams and Kamat, {Ashish M.}",
year = "2015",
doi = "10.1007/s11864-014-0315-3",
language = "English (US)",
volume = "16",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Immune Therapies in Non-Muscle Invasive Bladder Cancer

AU - Ho, Philip L.

AU - Williams, Stephen

AU - Kamat, Ashish M.

PY - 2015

Y1 - 2015

N2 - Non-muscle invasive bladder cancer (NMIBC) continues to be a challenging disease to manage. Treatment involves transurethral resection and, often, intravesical therapy. Appropriate patient selection, accurate staging, and morphological characterization are vital in risk-stratifying patients to those who would most benefit from receiving intravesical therapy. Bacillus of Calmette and Guérin (BCG) continues to be the first-line agent of choice for patients with intermediate- and high-risk NMIBC. Treatment should begin with the standard induction course of 6 weekly treatments. The inclusion of subsequent maintenance courses of BCG is imperative to optimal therapeutic response. While patients with intermediate-risk disease should receive 1 year of maintenance therapy, high-risk patients benefit from up to 3 years of maintenance therapy. BCG use should not be used in low-risk patients with de novo Ta, low-grade, solitary,

AB - Non-muscle invasive bladder cancer (NMIBC) continues to be a challenging disease to manage. Treatment involves transurethral resection and, often, intravesical therapy. Appropriate patient selection, accurate staging, and morphological characterization are vital in risk-stratifying patients to those who would most benefit from receiving intravesical therapy. Bacillus of Calmette and Guérin (BCG) continues to be the first-line agent of choice for patients with intermediate- and high-risk NMIBC. Treatment should begin with the standard induction course of 6 weekly treatments. The inclusion of subsequent maintenance courses of BCG is imperative to optimal therapeutic response. While patients with intermediate-risk disease should receive 1 year of maintenance therapy, high-risk patients benefit from up to 3 years of maintenance therapy. BCG use should not be used in low-risk patients with de novo Ta, low-grade, solitary,

KW - BCG

KW - Bladder Cancer

KW - Immune Therapy

KW - Immunology

KW - Non Invasive

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84924785519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924785519&partnerID=8YFLogxK

U2 - 10.1007/s11864-014-0315-3

DO - 10.1007/s11864-014-0315-3

M3 - Article

VL - 16

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 2

ER -